
Stacy Brown Chen
Examiner (ID: 11117, Phone: (571)272-0896 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1672, 1671 |
| Total Applications | 1660 |
| Issued Applications | 921 |
| Pending Applications | 198 |
| Abandoned Applications | 572 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17981254
[patent_doc_number] => 20220347290
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => HCoV IMMUNOGENIC BOOSTER COMPOSITION FOR IMPROVING IMMUNITYAGAINST SARS-COV-2 INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/869306
[patent_app_country] => US
[patent_app_date] => 2022-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5970
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17869306
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/869306 | HCoV immunogenic booster composition for improving immunityagainst SARS-COV-2 infection | Jul 19, 2022 | Issued |
Array
(
[id] => 18272458
[patent_doc_number] => 20230093700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => Virus-Like Particle Conjugates
[patent_app_type] => utility
[patent_app_number] => 17/857303
[patent_app_country] => US
[patent_app_date] => 2022-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2242
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17857303
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/857303 | Virus-like particle conjugates | Jul 4, 2022 | Issued |
Array
(
[id] => 19731126
[patent_doc_number] => 12209117
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Monoclonal antibodies and cocktails for treatment of Ebola infections
[patent_app_type] => utility
[patent_app_number] => 17/856774
[patent_app_country] => US
[patent_app_date] => 2022-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 15418
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17856774
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/856774 | Monoclonal antibodies and cocktails for treatment of Ebola infections | Jun 30, 2022 | Issued |
Array
(
[id] => 20129153
[patent_doc_number] => 12371455
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Sapovirus vaccines
[patent_app_type] => utility
[patent_app_number] => 17/851492
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 18288
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851492
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851492 | Sapovirus vaccines | Jun 27, 2022 | Issued |
Array
(
[id] => 18517634
[patent_doc_number] => 11707504
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-07-25
[patent_title] => Fusion peptide inhibitors of human coronavirus 229E
[patent_app_type] => utility
[patent_app_number] => 17/850400
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 2635
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850400
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850400 | Fusion peptide inhibitors of human coronavirus 229E | Jun 26, 2022 | Issued |
Array
(
[id] => 18374447
[patent_doc_number] => 20230149526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/841267
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841267
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/841267 | COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF | Jun 14, 2022 | Pending |
Array
(
[id] => 18183962
[patent_doc_number] => 20230044692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => HUMAN CYTOMEGALOVIRUS VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/839401
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839401
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/839401 | HUMAN CYTOMEGALOVIRUS VACCINE | Jun 12, 2022 | Abandoned |
Array
(
[id] => 18194460
[patent_doc_number] => 20230047979
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => DURABLE VACCINATION
[patent_app_type] => utility
[patent_app_number] => 17/838114
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76231
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17838114
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/838114 | DURABLE VACCINATION | Jun 9, 2022 | Pending |
Array
(
[id] => 20142800
[patent_doc_number] => 12377115
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Combination immunotherapies for treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 17/837294
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 18
[patent_no_of_words] => 29338
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837294
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/837294 | Combination immunotherapies for treatment of cancer | Jun 9, 2022 | Issued |
Array
(
[id] => 18182148
[patent_doc_number] => 20230042877
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => NOVEL METHODS OF GENERATING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/835370
[patent_app_country] => US
[patent_app_date] => 2022-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75182
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835370
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/835370 | NOVEL METHODS OF GENERATING ANTIBODIES | Jun 7, 2022 | Pending |
Array
(
[id] => 19382289
[patent_doc_number] => 20240272159
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => SENSOR FOR DETECTING BIOMARKERS IN A FLUID SAMPLE AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/566986
[patent_app_country] => US
[patent_app_date] => 2022-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24740
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566986
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/566986 | SENSOR FOR DETECTING BIOMARKERS IN A FLUID SAMPLE AND METHODS OF USE | Jun 5, 2022 | Pending |
Array
(
[id] => 17981252
[patent_doc_number] => 20220347288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => METHOD FOR PRODUCING ARTIFICIAL RECOMBINANT ROTAVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/805419
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16052
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17805419
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/805419 | Method for producing artificial recombinant rotavirus | Jun 2, 2022 | Issued |
Array
(
[id] => 18034689
[patent_doc_number] => 20220378904
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => HMPV MRNA VACCINE COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/737581
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737581
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/737581 | HMPV MRNA VACCINE COMPOSITION | May 4, 2022 | Abandoned |
Array
(
[id] => 20453244
[patent_doc_number] => 12516296
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Vaccines for treating SARS infections in cancer patients
[patent_app_type] => utility
[patent_app_number] => 17/730043
[patent_app_country] => US
[patent_app_date] => 2022-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 58
[patent_no_of_words] => 21462
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17730043
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/730043 | Vaccines for treating SARS infections in cancer patients | Apr 25, 2022 | Issued |
Array
(
[id] => 18574298
[patent_doc_number] => 11730804
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-08-22
[patent_title] => Compositions and methods for the prevention and treatment of rabies virus infection
[patent_app_type] => utility
[patent_app_number] => 17/720002
[patent_app_country] => US
[patent_app_date] => 2022-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 18770
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17720002
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/720002 | Compositions and methods for the prevention and treatment of rabies virus infection | Apr 12, 2022 | Issued |
Array
(
[id] => 17790564
[patent_doc_number] => 20220249655
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS)
[patent_app_type] => utility
[patent_app_number] => 17/715945
[patent_app_country] => US
[patent_app_date] => 2022-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17715945
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/715945 | AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS) | Apr 6, 2022 | Abandoned |
Array
(
[id] => 18909314
[patent_doc_number] => 11872277
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Compositions and methods related to ebolavirus vaccines
[patent_app_type] => utility
[patent_app_number] => 17/715658
[patent_app_country] => US
[patent_app_date] => 2022-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 56
[patent_no_of_words] => 21695
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17715658
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/715658 | Compositions and methods related to ebolavirus vaccines | Apr 6, 2022 | Issued |
Array
(
[id] => 19273268
[patent_doc_number] => 12023375
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
[patent_app_type] => utility
[patent_app_number] => 17/713149
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 30
[patent_no_of_words] => 21532
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17713149
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/713149 | Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling | Apr 3, 2022 | Issued |
Array
(
[id] => 19593171
[patent_doc_number] => 12150989
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-26
[patent_title] => Covalently modified antigens for improved immune response and/or stability
[patent_app_type] => utility
[patent_app_number] => 17/709599
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 68
[patent_no_of_words] => 15465
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709599
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/709599 | Covalently modified antigens for improved immune response and/or stability | Mar 30, 2022 | Issued |
Array
(
[id] => 19216333
[patent_doc_number] => 20240181037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => IMMUNOGENIC COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/283601
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283601
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/283601 | IMMUNOGENIC COMPOSITIONS | Mar 24, 2022 | Pending |